8-K: Karyopharm Secures $30M, SENTRY Trial Hits Spleen Goal

Karyopharm Therapeutics announced a $30 million private placement and positive spleen volume reduction results from its Phase 3 SENTRY myelofibrosis trial, though a symptom endpoint was missed and DLBCL approval is being withdrawn.

Summary

• Karyopharm Therapeutics Inc. entered into a Securities Purchase Agreement with RA Capital Management for a private placement expected to generate approximately $30 million in gross proceeds at closing, with an additional $44 million if accompanying warrants are fully exercised.
• The private placement involves the sale of 1,030,354 shares of common stock at $6.785 per share, 3,391,164 pre-funded warrants at $6.7849 per warrant, and accompanying warrants to purchase 4,421,518 shares of common stock at an exercise price of $10.00 per share.
• Proceeds from the private placement will be used for general corporate purposes, including ongoing and planned clinical trial activities, and are expected to extend the company's cash runway into late Q3 2026.
• The Phase 3 SENTRY trial for selinexor in combination with ruxolitinib in frontline myelofibrosis met its first co-primary endpoint, demonstrating a statistically significant improvement in spleen volume reduction of 35% or more (SVR35) at week 24 (50% for combination vs. 28% for ruxolitinib alone, one-sided p<0.0001).
• The SENTRY trial did not meet its second co-primary endpoint, as similar symptom improvement from baseline was observed across both arms (9.89 point improvement for combination vs. 10.86 for ruxolitinib alone, not statistically significant).
• A promising overall survival (OS) signal was observed in the SENTRY trial for the combination arm with a hazard ratio of 0.43 (95% CI [0.19, 1.00], nominal one-sided p=0.0222), which the company intends to follow to maturity.
• Evidence of potential disease modification was observed in the SENTRY trial, with 32% of combination patients achieving a >=20% reduction in Variant Allele Frequency (VAF) for JAK2, MPL, and CALR mutations at week 24, compared to 24% for ruxolitinib alone.
• The combination therapy in the SENTRY trial demonstrated a manageable safety and tolerability profile consistent with the known profiles of selinexor and ruxolitinib individually, with no new safety signals.
• Karyopharm will voluntarily withdraw the accelerated approval for XPOVIO (selinexor) in Diffuse Large B-Cell Lymphoma (DLBCL) at the FDA's request, due to the inability to complete the confirmatory trial and the evolving treatment landscape, noting immaterial revenue from DLBCL sales.
• In March 2026, the company issued and sold 1,100,844 shares of Common Stock under its At-The-Market (ATM) facility, generating approximately $9.6 million in net proceeds.
• The proceeds from the private placement will satisfy the capital raise trigger condition for the effectiveness of the Second Amendment to Credit and Guaranty Agreement and the Forbearance Agreement, both dated February 27, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but slightly positive development. The successful SVR35 endpoint and promising OS signal in the SENTRY trial are significant, but the missed symptom endpoint and the withdrawal of the DLBCL indication temper enthusiasm. The capital raise provides necessary liquidity.

Positives

• The Phase 3 SENTRY trial met its first co-primary endpoint, demonstrating a statistically significant improvement in spleen volume reduction of 35% or more (SVR35) at week 24 (50% for combination vs. 28% for ruxolitinib alone, one-sided p<0.0001).
• A promising overall survival (OS) signal was observed in the SENTRY trial for the combination arm with a hazard ratio of 0.43 (95% CI [0.19, 1.00], nominal one-sided p=0.0222), suggesting a significant reduction in the risk of death.
• Evidence of potential disease modification was noted with 32% of combination patients achieving a >=20% reduction in Variant Allele Frequency (VAF) for key driver mutations, compared to 24% for ruxolitinib alone.
• The private placement is expected to provide approximately $30 million in gross proceeds at closing, with potential for an additional $44 million from warrant exercise, extending the cash runway into late Q3 2026.
• The capital raise satisfies a trigger condition for the effectiveness of the Second Amendment to Credit and Guaranty Agreement and the Forbearance Agreement, improving the company's financial flexibility.

Negatives

• The Phase 3 SENTRY trial did not meet its second co-primary endpoint, as the difference in absolute total symptom score (Abs-TSS) improvement between the combination and ruxolitinib alone was not statistically significant (one-sided p=0.8246).
• The company will voluntarily withdraw the accelerated approval for XPOVIO in Diffuse Large B-Cell Lymphoma (DLBCL) at the FDA's request due to the inability to complete the confirmatory trial, representing a loss of an approved indication.
• The combination arm in the SENTRY trial showed a higher rate of Grade 3+ treatment emergent adverse events (TEAEs) (70% vs. 50%) and TEAEs leading to treatment discontinuation (15% vs. 9%) compared to ruxolitinib alone.

Risks

• The company faces risks related to the inability to complete confirmatory trials, as demonstrated by the withdrawal of the DLBCL indication due to impractical study design.
• Future regulatory approvals for selinexor in myelofibrosis are not guaranteed, as the company still needs to meet with the FDA to discuss the totality of the SENTRY data and its sNDA filing plan.
• The forward-looking statements indicate substantial doubt exists regarding Karyopharm's ability to continue as a going concern, highlighting ongoing financial risks.
• There is a risk that positive developments in drug candidate development or commercialization may not translate into stock price appreciation.
• The company's ability to obtain, maintain, and enforce patent and other intellectual property protection for its products or product candidates is a continuous risk.

Future Outlook

The company expects the net proceeds from the private placement, combined with existing liquidity and cash flow, to fund its operating plans into late Q3 2026. Plans include meeting with the U.S. Food and Drug Administration (FDA) to discuss the totality of the SENTRY trial data and its supplemental new drug application (sNDA) filing plan. Additional data from the Phase 3 SENTRY trial will be shared at an upcoming medical meeting, and a manuscript is expected to be submitted to a peer-reviewed medical journal, with potential inclusion in relevant compendia in the second half of 2026. Topline data from the Phase 2 SENTRY-2 trial (60 mg cohort) is expected in the second half of 2026, and topline data from the Phase 3 XPORT-EC-042 trial for endometrial cancer is expected in mid-2026. The company will cease further clinical development and related operational expenses for the DLBCL indication following its voluntary withdrawal of accelerated approval.

Management Comments

• "The results from SENTRY are an important development for patients as the combination of selinexor plus ruxolitinib meaningfully improved spleen response and we observed a promising signal in overall survival." Dr. John Mascarenhas, Principal Investigator of Phase 3 SENTRY Trial.
• "The SENTRY topline results suggest that the combination of selinexor and ruxolitinib delivers superior spleen reduction, which may predict overall survival, while offering similar symptom improvement, and may offer an important advance for our patients." Dr. Claire Harrison, Professor of Myeloproliferative Neoplasms and Deputy Chief Medical Officer of Research, Data, and Analytics at Guys and St. Thomas NHS Foundation Trust.
• "I am encouraged by the speed and magnitude of spleen response, and the promising overall survival signal and evidence of potential disease modification. In totality, these data underscore selinexor’s potential to meaningfully improve clinical outcomes for patients with myelofibrosis." Reshma Rangwala, MD, PhD, Chief Medical Officer and Head of Research of Karyopharm.
• "The myelofibrosis community is waiting for new treatment options that can build upon the benefit of JAK inhibitors. Improving overall survival is the ultimate goal for people living with myelofibrosis and I am incredibly encouraged by these results." Kapila Viges, Chief Executive Officer of the MPN Research Foundation.

Industry Context

StockSavvy.ai notes that the myelofibrosis treatment landscape has a high unmet need for novel mechanisms beyond existing JAK inhibitors like ruxolitinib. Selinexor's XPO1 inhibition offers a differentiated approach, potentially targeting biological pathways not addressed by JAK signaling alone. The positive SVR35 and promising OS signal from the SENTRY trial could position selinexor as a significant advance, especially given the established link between SVR35 and improved overall survival in myelofibrosis. The withdrawal of the DLBCL accelerated approval highlights the inherent challenges and evolving treatment paradigms in oncology drug development, where confirmatory trials can become impractical, leading to strategic portfolio adjustments.

Comparison to Industry Standards

• The SENTRY trial's 50% SVR35 rate at week 24 for the selinexor-ruxolitinib combination significantly outperforms the 28% rate for ruxolitinib alone, and compares favorably to historical ruxolitinib-alone arms in other myelofibrosis studies such as SIMPLIFY-1, MANIFEST-2, and Transform-1, which typically show lower SVR35 rates.
• The promising overall survival (OS) signal with a hazard ratio of 0.43 for the combination arm suggests a substantial reduction in the risk of death, which is a critical outcome in myelofibrosis where median survival for intermediate-to-high risk patients is often limited to 4-5 years.
• While the combination did not achieve statistical significance for symptom improvement (Abs-TSS), the observed similar improvement from baseline (9.89 vs. 10.86 points) indicates it did not detract from a key benefit of existing JAK inhibitor therapy.
• The 32% VAF reduction in the combination arm, compared to 24% for ruxolitinib alone, suggests potential disease modification, a feature that could differentiate selinexor from current standard-of-care JAK inhibitors which primarily focus on symptom and spleen control.

Stakeholder Impact

• Shareholders: Potential for share price volatility due to mixed clinical trial results and the withdrawal of an approved indication. Dilution from the private placement and ATM sales.
• Patients (Myelofibrosis): Potential for a new, more effective treatment option with selinexor in combination with ruxolitinib, particularly for spleen reduction and overall survival.
• Patients (DLBCL): Loss of an accelerated approval treatment option for relapsed or refractory DLBCL, though the company notes immaterial revenue from this indication.
• Employees: Strategic shift in R&D focus away from DLBCL, potentially impacting related teams.
• Creditors: Satisfaction of capital raise trigger condition for credit and forbearance agreements may improve the company's standing with creditors.

Next Steps

• Meet with the U.S. Food and Drug Administration (FDA) to discuss the totality of the SENTRY trial data and its supplemental new drug application (sNDA) filing plan.
• Share additional data from the Phase 3 SENTRY trial at an upcoming medical meeting.
• Submit a manuscript detailing SENTRY trial results to a peer-reviewed medical journal.
• Seek potential inclusion of SENTRY trial results in relevant compendia in the second half of 2026.
• Await topline data from the 60 mg cohort of the Phase 2 SENTRY-2 trial in the second half of 2026.
• Await topline data from the event-driven, Phase 3 XPORT-EC-042 trial for endometrial cancer in mid-2026.
• Cease ongoing and any further clinical development and related operational expenses for the DLBCL indication.

Key Dates

Recommendation

The stock is recommended as a 'hold' due to a mixed bag of significant developments. The positive spleen volume reduction and promising overall survival signal from the SENTRY trial offer potential upside for a high-unmet-need indication. However, the missed symptom endpoint in the same trial and the voluntary withdrawal of the DLBCL accelerated approval represent clear setbacks. The capital raise provides necessary liquidity but also involves dilution. Investors should monitor the FDA discussions for myelofibrosis and the progress of other pipeline assets, as the current situation presents both opportunities and notable risks.

Keywords

Karyopharm, KPTI, Selinexor, XPOVIO, Myelofibrosis, SENTRY trial, Oncology, Cancer therapy, Private placement, Warrants, Clinical trial, FDA, DLBCL, Drug development, Biotechnology, Pharmaceutical